Geyer Alexander I, Metersky Mark L
Division of Pulmonary, Critical Care and Sleep Medicine, Lenox Hill Hospital, New York, NY, USA.
Division of Pulmonary, Critical Care and Sleep Medicine, UConn Health, Farmington, CT, USA.
Expert Rev Respir Med. 2025 Aug;19(8):767-774. doi: 10.1080/17476348.2025.2508313. Epub 2025 May 22.
Non-cystic-fibrosis bronchiectasis (NCFB) is an airway disorder with a growing worldwide prevalence that affects predominantly older and female individuals and is associated with high symptom burden and significant healthcare expenditure. Brensocatib is a novel orally bioavailable, selective, and reversible dipeptidyl peptidase 1 (DPP1) inhibitor that leads to a sustained inhibition of neutrophil serine protease activity in both whole blood and sputum.
This drug profile summarizes the role of inflammation in the pathophysiology of bronchiectasis. The mechanism of action of brensocatib in reducing neutrophil-related inflammation is described. We then summarize existing efficacy and safety data from Phase 2 and Phase 3 studies of brensocatib in patients with bronchiectasis, in which the rate of exacerbation was the primary endpoint. Finally, we summarize the current marketplace for brensocatib, including the unmet for effective therapies for bronchiectasis, and the status of other potential treatments undergoing clinical trials.
Brensocatib is a first-in-class DPP1 inhibitor that shows promise as a treatment for patients with bronchiectasis.
非囊性纤维化支气管扩张症（NCFB）是一种气道疾病，在全球范围内的患病率不断上升，主要影响老年人和女性，伴有较高的症状负担和可观的医疗支出。布瑞索卡特（Brensocatib）是一种新型的口服生物可利用、选择性且可逆的二肽基肽酶1（DPP1）抑制剂，可在全血和痰液中持续抑制中性粒细胞丝氨酸蛋白酶活性。
本药物简介总结了炎症在支气管扩张症病理生理学中的作用。描述了布瑞索卡特在减轻中性粒细胞相关炎症方面的作用机制。然后，我们总结了布瑞索卡特在支气管扩张症患者中的2期和3期研究的现有疗效和安全性数据，其中恶化率是主要终点。最后，我们总结了布瑞索卡特目前的市场情况，包括支气管扩张症有效治疗方法的未满足需求，以及其他正在进行临床试验的潜在治疗方法的状况。
布瑞索卡特是一流的DPP1抑制剂，有望成为支气管扩张症患者的治疗药物。
